![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ADGRE5 |
Gene summary for ADGRE5 |
![]() |
Gene information | Species | Human | Gene symbol | ADGRE5 | Gene ID | 976 |
Gene name | adhesion G protein-coupled receptor E5 | |
Gene Alias | CD97 | |
Cytomap | 19p13.12 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | P48960 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
976 | ADGRE5 | LZE24T | Human | Esophagus | ESCC | 8.00e-08 | 2.43e-01 | 0.0596 |
976 | ADGRE5 | LZE6T | Human | Esophagus | ESCC | 1.30e-12 | 6.10e-01 | 0.0845 |
976 | ADGRE5 | P2T-E | Human | Esophagus | ESCC | 9.86e-06 | 2.24e-02 | 0.1177 |
976 | ADGRE5 | P5T-E | Human | Esophagus | ESCC | 6.31e-08 | 1.60e-01 | 0.1327 |
976 | ADGRE5 | P8T-E | Human | Esophagus | ESCC | 2.92e-13 | 2.33e-01 | 0.0889 |
976 | ADGRE5 | P10T-E | Human | Esophagus | ESCC | 3.99e-02 | -2.23e-02 | 0.116 |
976 | ADGRE5 | P11T-E | Human | Esophagus | ESCC | 8.86e-10 | 4.87e-01 | 0.1426 |
976 | ADGRE5 | P16T-E | Human | Esophagus | ESCC | 1.26e-04 | -4.98e-03 | 0.1153 |
976 | ADGRE5 | P19T-E | Human | Esophagus | ESCC | 5.03e-07 | 3.88e-01 | 0.1662 |
976 | ADGRE5 | P21T-E | Human | Esophagus | ESCC | 2.24e-16 | 3.67e-01 | 0.1617 |
976 | ADGRE5 | P22T-E | Human | Esophagus | ESCC | 2.17e-03 | -1.15e-02 | 0.1236 |
976 | ADGRE5 | P23T-E | Human | Esophagus | ESCC | 9.64e-06 | 1.88e-01 | 0.108 |
976 | ADGRE5 | P24T-E | Human | Esophagus | ESCC | 1.25e-07 | 1.68e-01 | 0.1287 |
976 | ADGRE5 | P26T-E | Human | Esophagus | ESCC | 1.05e-12 | 1.83e-01 | 0.1276 |
976 | ADGRE5 | P27T-E | Human | Esophagus | ESCC | 4.47e-02 | -1.45e-02 | 0.1055 |
976 | ADGRE5 | P28T-E | Human | Esophagus | ESCC | 8.22e-15 | 2.80e-01 | 0.1149 |
976 | ADGRE5 | P31T-E | Human | Esophagus | ESCC | 1.00e-05 | 1.90e-01 | 0.1251 |
976 | ADGRE5 | P32T-E | Human | Esophagus | ESCC | 1.06e-15 | 1.87e-01 | 0.1666 |
976 | ADGRE5 | P37T-E | Human | Esophagus | ESCC | 1.96e-08 | 2.19e-01 | 0.1371 |
976 | ADGRE5 | P39T-E | Human | Esophagus | ESCC | 1.94e-02 | -2.50e-02 | 0.0894 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Breast | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Breast | DCIS |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Breast | Healthy |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Breast | IDC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Cervix | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Cervix | CC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Cervix | Healthy |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | CRC | Healthy |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | CRC | MSI-H |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | CRC | MSS |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Endometrium | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Endometrium | AEH |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Endometrium | EEC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Endometrium | Healthy |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | Esophagus | ESCC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | GC | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | GC | GC |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | GC | Precancer |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | HNSCC | ADJ |
ADGRE5 | CD55 | ADGRE5_CD55 | ADGRE5 | HNSCC | Healthy |
Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADGRE5 | SNV | Missense_Mutation | rs748373111 | c.1531G>A | p.Glu511Lys | p.E511K | P48960 | protein_coding | tolerated(0.44) | benign(0.078) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ADGRE5 | SNV | Missense_Mutation | c.586N>A | p.Pro196Thr | p.P196T | P48960 | protein_coding | tolerated(0.06) | benign(0.044) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ADGRE5 | SNV | Missense_Mutation | novel | c.1315N>A | p.Leu439Ile | p.L439I | P48960 | protein_coding | tolerated(0.4) | benign(0.01) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ADGRE5 | SNV | Missense_Mutation | rs750288090 | c.215C>T | p.Ser72Leu | p.S72L | P48960 | protein_coding | tolerated(0.82) | benign(0.003) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ADGRE5 | SNV | Missense_Mutation | novel | c.517N>T | p.Ser173Cys | p.S173C | P48960 | protein_coding | deleterious(0.04) | possibly_damaging(0.84) | TCGA-DD-AACL-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ADGRE5 | SNV | Missense_Mutation | rs781751037 | c.239N>T | p.Ser80Leu | p.S80L | P48960 | protein_coding | deleterious(0) | possibly_damaging(0.623) | TCGA-DD-AAE0-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ADGRE5 | deletion | Frame_Shift_Del | novel | c.1709delN | p.Leu570ArgfsTer61 | p.L570Rfs*61 | P48960 | protein_coding | TCGA-DD-A73D-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
ADGRE5 | SNV | Missense_Mutation | c.757G>C | p.Asp253His | p.D253H | P48960 | protein_coding | deleterious(0.05) | possibly_damaging(0.649) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ADGRE5 | SNV | Missense_Mutation | novel | c.1230G>T | p.Leu410Phe | p.L410F | P48960 | protein_coding | tolerated(0.05) | benign(0.334) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
ADGRE5 | SNV | Missense_Mutation | novel | c.916N>A | p.Asp306Asn | p.D306N | P48960 | protein_coding | deleterious(0.04) | possibly_damaging(0.76) | TCGA-38-4626-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |